Aastrom Biosciences, Inc. (NASDAQ:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, on 9 April announced that the independent Data and Safety Monitoring Board (DSMB) for the company’s ixCELL-DCM Phase 2b clinical trial has recommended continuing the study without modification as planned following an interim review of unblinded safety data from the trial. Aastrom Biosciences Inc. (NASDAQ:ASTM) shares after opening at $4.00 moved to $4.95 on last trade day and at the end of the day closed at $4.38. Company price to sales ratio in past twelve months was calculated as 1426.96 and price to cash ratio as 3.35. Aastrom Biosciences Inc. (NASDAQ:ASTM) showed a positive weekly performance of 20.66%.
Emerging pharmaceutical company, ANI Pharmaceuticals Inc. (NASDAQ:ANIP), recently announced the extension of a fee for service product development agreement with Sterling Pharmaceutical Services. ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares advanced 20.67% in last trading session and ended the day on $30.83. ANIP return on equity ratio is recorded as -20.10% and its return on assets is -17.00%. ANI Pharmaceuticals Inc. (NASDAQ:ANIP) yearly performance is 346.81%.
Veracyte Inc. (NASDAQ:VCYT) revenue increased $10.4 million, or 89%, from $11.6 million for the year ended December 31, 2012 to $21.9 million for the year ended December 31, 2013, and $9.0 million, or 340%, from $2.6 million for the year ended December 31, 2011 to $11.6 million for the year ended December 31, 2012. Veracyte Inc. (NASDAQ:VCYT) shares moved down -1.80% in last trading session and was closed at $13.06, while trading in range of $13.00 – $13.43. Veracyte Inc. (NASDAQ:VCYT) year to date (YTD) performance is -9.93%.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) yesterday announced that it would submit a new drug application before Food and Drug Administration (FDA) for its experimental treatment for a fatal degenerative disease that causes trouble to the children. The company is expected to submit the application later this year. Sarepta Therapeutics Inc. (NASDAQ:SRPT) weekly performance is 53.20%. On last trading day company shares ended up $33.98. Sarepta Therapeutics Inc. (NASDAQ:SRPT) distance from 50-day simple moving average (SMA50) is 29.14%. Analysts mean target price for the company is $25.50.